Phase I Data on Anti-Notch1 Selected for Oral Plenary Presentation
REDWOOD CITY, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present clinical data from three anti-cancer stem cell clinical programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting to be held November 18-21, 2014 in Barcelona, Spain.
Among the presentations will be clinical data from OncoMed's anti-Notch1 (OMP-52M51) solid tumor clinical trial. Interim results from the Phase 1a study have been selected for an oral plenary session presentation. Additional data will be presented from the demcizumab (anti-DLL4, OMP-21M18) and tarextumab (anti-Notch2/3, OMP-59R5) programs.
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=879319
OncoMed to Present Clinical and Preclinical Data at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting
Wright Medical Group Inc. (WMGI:US), a U.S. maker of bone implants, will merge with Tornier NV, creating a new company valued at $3.3 billion in the latest proposed tax inversion since tighter rules were announced last month.
The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease
Via: Business Wire
MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix® 035 Drug Coated Balloon (DCB) Catheter for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA’s Circulatory Systems Devices Advisory Panel in June 2014. The Lutonix® 035 DCB—the first and only FDA-approved DCB in the U.S.— is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.